United States ex rel. Root v. UCB, Inc. (District of Columbia)

New England native Brian Root filed this qui tam action against his former employer, a Belgian pharmaceutical company. The 2011 settlement totaled over $ 25 million.  Relator Root reported that UCB was marketing the drug Keppra for uses not approved by the FDA. Keppra is a drug used for treatment of certain types of epilepsy patients only. UCB was rewarding its salesforce with extra compensation for these "off label" sales and was requiring sales representatives to call upon medical professionals whose medical practices were not likely to involve treatment of patients for whom Keppra was appropriate. The United States Justice Department intervened in the action and UCB plead guilty to criminal charges. 


Under the applicable law of some states, this website is an advertisement. The hiring of an attorney is an important decision that should not be based solely upon advertisements, certifications, or specializations. Please note that the material on this website is general information only, and not offered as legal advice on any matter. This website will not be responsible for any action or failure to act in reliance upon information on this website or any third-party website that may be accessible through a link on this website. In addition, our operation of this website is not intended to create, and will not create, an attorney-client relationship with you. Listing of related or included practice areas herein reflects a focus of an attorney's practice and does not constitute or imply a representation of certification or specialization.